GBI Research's latest report, ""Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets"" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.
Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.
HEOR plays a critical part in market access
HTA has gained importance in reimbursement decisions
Pricing and reimbursement are the key elements of market access
Reasons to buy
This report will allow you to -
Table of Content
Health Economic and Outcomes Research (HEOR)
A Systemic Value Development Plan for HEOR
Types of Economic Evaluations
Overview of Cost-Effectiveness Analysis
Quality-Adjusted Life Year in HEOR
Pharmacoeconomic Modelling Methods
Health Technology Assessment (HTA) in Market Access
Key Benefits of HTA
Process and Dimensions of HTA
Principle HTA Regulatory Agencies
Risk Sharing Agreements When Limited Evidence is Available for HTA
Pricing and Reimbursement
Factors Affecting Pricing Decision
Pricing of a New Drug
Pharmaceutical Pricing Policies in the US
Impact Of Affordable Care Act on Market Access
Pharmaceutical Pricing and Reimbursement Policies in Canada
Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)
Parallel Trade in Europe
Pharmaceutical Pricing and Reimbursement Policies in Japan
Economic Analysis Alongside Clinical Trials
Harmonization of Drug Approval and Marketing for Effective Market Access
Key Challenges for Achieving Optimum Market Access
Make an enquiry before buying this Report
Please fill the enquiry form below.
Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and blood cancers due to aging, infections, exposure to certain chemicals, smoking, genetic disorders and other factors. Hence, the category of blood disorders is wide and numerous types of diseases fall under it. There are three main types of cancer that affect blood namely leukemia which affect...
Ocular pain is also known as eye pain that occurs on the surface of the eye. Ocular pain is considered as a common medical condition that resolves on its own but, sometimes it creates emergency medical conditions. Possible causes for ocular pain includes corneal discomfort, pain in the sclera and discomfort in conjunctiva and pain in the iris. Moreover, few other etiology of ocular pain includes pain in extracellular muscle of the eye, burning se...
Apoptosis is the death of cell in a programmed fashion that is observed largely in multicellular organisms. This programmed cell death occurs in a cascade of biochemical events which include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation and chromosomal fragmentation. Anywhere between 50 and 70 billion cells die each day due to apoptosis in the average human adult. This cascade has been hypothesized to be exploited as a...